Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 6
2003 5
2004 6
2005 5
2006 9
2007 11
2008 14
2009 11
2010 10
2011 21
2012 13
2013 19
2014 15
2015 16
2016 15
2017 18
2018 15
2019 20
2020 15
2021 27
2022 25
2023 25
2024 11
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Results by year

Filters applied: . Clear all
Page 1
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action.
Czupryniak L, Mosenzon O, Rychlík I, Clodi M, Ebrahimi F, Janez A, Kempler P, Małecki M, Moshkovich E, Prázný M, Sourij H, Tankova T, Timar B. Czupryniak L, et al. Among authors: malecki m. Diabetes Obes Metab. 2024 Oct;26(10):4165-4177. doi: 10.1111/dom.15789. Epub 2024 Aug 14. Diabetes Obes Metab. 2024. PMID: 39140231 Review.
Treatment of type 2 diabetes mellitus. Introduction.
Shafrir E, Malecki M, Schernthaner G, Kiljanski J. Shafrir E, et al. Among authors: malecki m. Diabetes Res Clin Pract. 2008 Dec 15;82 Suppl 2:S81-2. doi: 10.1016/j.diabres.2008.09.019. Epub 2008 Nov 18. Diabetes Res Clin Pract. 2008. PMID: 19019474 No abstract available.
Gene therapy.
Małecki M. Małecki M. Med Wieku Rozwoj. 2013 Jul-Sep;17(3):189-90. Med Wieku Rozwoj. 2013. PMID: 24296441 No abstract available.
Variants influencing age at diagnosis of HNF1A-MODY.
Ludwig-Słomczyńska AH, Seweryn MT, Radkowski P, Kapusta P, Machlowska J, Pruhova S, Gasperikova D, Bellanne-Chantelot C, Hattersley A, Kandasamy B, Letourneau-Freiberg L, Philipson L, Doria A, Wołkow PP, Małecki MT, Klupa T. Ludwig-Słomczyńska AH, et al. Among authors: malecki mt. Mol Med. 2022 Sep 14;28(1):113. doi: 10.1186/s10020-022-00542-0. Mol Med. 2022. PMID: 36104811 Free PMC article.
305 results